Prevacid

[Lansoprazole]

Pediatric (short-term treatment of
symptomatic GERD, short-term treatment of
erosive esophagitis) (1 – 11 years of age) 30 kg
> 30 kg 15 mg 30 mg Once daily for up to 12 weeks
+
Once daily for up to 12 weeks +

PEDIATRIC USE

Maintenance of Healing of Erosive Esophagitis 15 mg Once daily CLINICAL STUDIES
Pathological Hypersecretory Conditions Including
Zollinger-Ellison Syndrome
60 mg Once daily*** CLINICAL STUDIES

Text Continues Below

---

* Please refer to amoxicillin and clarithromycin full prescribing information for CONTRAINDICATIONS and WARNINGS, and for information regarding dosing in elderly and renally-impaired patients.

* Controlled studies did not extend beyond indicated duration.

PREVACID

** For patients who do not heal with PREVACID for 8 weeks (5– 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis, an additional 8 week course of PREVACID may be considered. *** Varies with individual patient. Recommended adult starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Dosages up to 90 mg b. i. d. have been administered. Daily dose of greater than 120 mg should be administered in divided doses. Some patients with Zollinger-Ellison Syndrome have been treated continuously with PREVACID for more than 4 years.

+ The PREVACID dose was increased (up to 30 mg b. i. d.) in some pediatric patients after 2 or more weeks of treatment if they remained symptomatic. For pediatric patients unable to swallow an intact capsule please see Administration Options.

Administration Options
1. PREVACID Delayed-Release Capsules
PREVACID Capsules-Oral Administration
PREVACID Delayed-Release Capsules should be swallowed whole.
Alternatively, for patients who have difficulty swallowing capsules, PREVACID Delayed-Release Capsules can be opened and administered as follows:

Page:  << Prev | 1 | 2 | 3 | 4 | 5 | Next >>